"I am extremely pleased to be joining Amarantus at this juncture as the Company prepares for listing on a national exchange in the coming months," said Mr. Huffman. "The Company has made substantial strides recently, positioning itself for significant growth, and I will work closely with the team to further these efforts. The set of assets assembled which span neurological, ophthalmological and metabolic indications is impressive, and being woven into a cohesive story around biological pathways. This is the future of how science, biology and medicine will interplay and I believe we are at the forefront. I am excited to begin my journey with Amarantus."

Read more: http://www.nasdaq.com/press-release/amarantus...z39wwE1W00